A phase 1/2 trial to assess safety and efficacy of a vaporized 5-methoxy-N,N-dimethyltryptamine formulation (GH001) in patients with treatment-resistant depression

Johannes T. Reckweg*, Cees J. van Leeuwen, Cecile Henquet, Therese van Amelsvoort, Eef L. Theunissen, Natasha L. Mason, Riccardo Paci, Theis H. Terwey, Johannes G. Ramaekers*

*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Fingerprint

Dive into the research topics of 'A phase 1/2 trial to assess safety and efficacy of a vaporized 5-methoxy-N,N-dimethyltryptamine formulation (GH001) in patients with treatment-resistant depression'. Together they form a unique fingerprint.

Keyphrases

INIS

Pharmacology, Toxicology and Pharmaceutical Science